The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| XCUR | +114.6% | -98% | -54.25% | -99% |
| S&P | +16.9% | +95.99% | +14.39% | +149% |
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.13M | 36.9% |
| Gross Margin | 59.80% | 0.0% |
| Market Cap | $44.48M | 1506.7% |
| Market Cap / Employee | $5.56M | 0.0% |
| Employees | 8 | 60.0% |
| Net Income | -$2.62M | -336.8% |
| EBITDA | -$2.32M | -124.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.86M | 1388.3% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.48M | -71.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -53.58% | 4.3% |
| Return On Invested Capital | -130.39% | -9.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.60M | -123.2% |
| Operating Free Cash Flow | -$2.28M | -95.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.72 | 19.22 | 11.87 | 3.91 | 211.54% |
| Price to Sales | 10.41 | 5.54 | 13.18 | 164.77 | - |
| Price to Tangible Book Value | 3.72 | 19.22 | 11.87 | 10.45 | 732.78% |
| Enterprise Value to EBITDA | -10.09 | -61.54 | -24.91 | -15.98 | 72.61% |
| Return on Equity | -132.6% | -197.9% | -86.3% | -150.5% | 4.22% |
| Total Debt | $6.13M | $5.94M | $0.62M | $0.48M | -93.49% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
